BTIG Research Reiterates Buy Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a report issued on Wednesday, Benzinga reports. They presently have a $8.00 price objective on the stock. BTIG Research’s price target would indicate a potential upside of 197.95% from the stock’s current price.

Several other research firms have also commented on ACIU. Weiss Ratings reissued a “sell (e+)” rating on shares of AC Immune in a research report on Wednesday, August 5th. HC Wainwright reissued a “buy” rating on shares of AC Immune in a research report on Monday, August 24th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, AC Immune currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

AC Immune Stock Down 5.1%

Shares of ACIU traded down $0.15 during trading hours on Wednesday, hitting $2.69. The company had a trading volume of 131,333 shares, compared to its average volume of 274,153. The company has a market capitalization of $273.25 million, a PE ratio of -4.97 and a beta of 1.60. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. AC Immune has a one year low of $2.10 and a one year high of $4.00. The company’s fifty day moving average price is $2.55 and its two-hundred day moving average price is $2.68.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.13. The firm had revenue of $18.67 million during the quarter, compared to analyst estimates of $9.59 million. AC Immune had a negative return on equity of 100.17% and a negative net margin of 245.32%. As a group, equities analysts forecast that AC Immune will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AXQ Capital LP purchased a new position in AC Immune during the 2nd quarter worth $25,000. Arrowstreet Capital Limited Partnership grew its stake in AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune News Roundup

Here are the key news stories impacting AC Immune this week:

• Positive Sentiment: Positive Phase 2 safety and immune-response data: Through week 100 of the VacSYn Phase 2 trial, ACI-7104 met all primary endpoints, was generally safe and well tolerated, and produced a 100% antibody response after three doses. Antibodies also penetrated the cerebrospinal fluid, with signals of target engagement—important evidence that the vaccine is reaching the central nervous system. AC Immune Phase 2 trial announcement
• Positive Sentiment: Analysts reaffirm bullish views: BTIG Research reiterated its Buy rating and set an $8 price target, implying substantial potential appreciation from the reference price of $2.71. H.C. Wainwright analyst Andrew Fein also maintained a Buy rating and $12 target, citing the VacSYn data as validation of AC Immune’s platform. BTIG Research rating H.C. Wainwright rating
• Neutral Sentiment: Development remains ongoing: The reported results primarily establish safety and immunogenicity, rather than demonstrating definitive clinical benefits for Parkinson’s patients. Part 2 of the trial is intended to assess clinical activity, and AC Immune expects to discuss the future development path with the FDA in early 2027. AC Immune Phase 2 results

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.